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Cardio-metabolic diseases (CMDs) comprise a cluster of risk factors that contribute to
chronic pathological conditions with adverse consequences for cardiovascular function
and metabolic processes. A wide range of CMD prevalence rates among different
ethnic groups has been documented. In view of accumulated evidence, there is a
trend toward increasing CMD prevalence rates in Eastern Europe and Western Asia.
Numerous studies have revealed an association between uncoupling protein 1 (UCP1)
gene variants and CMDs. UCP1 activity is essential for brown adipose tissue (BAT)-
mediated thermogenesis. Experimental animal studies and epidemiological studies in
humans highlight the significance of BAT-mediated thermogenesis in protecting against
obesity and maintaining a lean phenotype. We hypothesize that the genetic variation
in UCP1 gene expression observed among different ethnic groups could contribute to
the ethnic-specific predisposition to CMD development. Constructing such prevalence
maps of UCP1 gene variants could contribute significantly into identifying high-risk
ethnic groups predisposed to the development of CMDs, and further shaping public
health policies by the improvement of existing preventive and management strategies.
Keywords: gene variants, cardio-metabolic diseases, uncoupling protein 1, brown adipose tissue, metabolism,
prevalence rates, ethnic groups, population studies
INTRODUCTION
The World Health Organization (WHO) estimates that by 2030 more than 23 million patients
affected by cardiovascular diseases (CVDs) – the leading cause of death globally – will die annually
(WHO, 2016a), while diabetes will become the seventh leading cause of death (WHO, 2016b).
In total, the European region has one of the highest mortality rates for adults under the age of
70 years due to a very high prevalence of cardio-metabolic diseases (CMDs) (Mathers et al., 2009;
WHO, 2014). CMDs comprise a cluster of risk factors that increase susceptibility to developing
CVDs, such as atherosclerosis and arterial thrombosis, metabolic syndrome, and type 2 diabetes
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mellitus, and its related metabolic traits. CMD-associated
risk factors among others include obesity, hypertension, low
high-density lipoprotein cholesterol, insulin resistance, glucose
intolerance, and elevated triglycerides (Grundy et al., 2004;
Cornelissen and Smart, 2013; Vissers et al., 2013; Conn et al.,
2014). Recently, the prevalence of obese individuals with
metabolic syndrome in a large cohort of participants across
Europe was estimated to reach as high as 78 and 65% in
males and females, respectively (van Vliet-Ostaptchouk et al.,
2014). Another example is a trend toward the increase in CVD
prevalence in certain ethnic groups in Eastern Europe and
Western Asia compared to Western Europe (Figure 1) (Balkau
et al., 2007; WHO, 2011).
The uncoupling protein-1 (UCP1) gene is located in
chromosome 4 of the human genome and is considered to be
involved in the pathogenesis of CMDs due to its major role in
thermogenesis and energy metabolism (Golozoubova et al., 2001;
Mattson, 2010). UCP1 is mainly expressed in brown adipose
tissue (BAT) and is located in the inner mitochondrial membrane
where it catalyzes proton leaks across the membrane, and thus
uncoupling oxidative phosphorylation from ATP production
(Tsuboyama-Kasaoka et al., 1998). This is proposed to lead to
energy dissipation in the form of heat, accompanied by an
increase in energy expenditure (Wu et al., 2013). It has been
suggested that BAT activity, mediated by UCP1 expression,
in humans can contribute to 5% of the basal metabolic rate
(van Marken Lichtenbelt and Schrauwen, 2011), indicative of a
regulatory role of BAT in energy balance and hence body weight.
In adult humans, the levels of UCP1 in BAT are diminished with
age and are negatively correlated to adiposity (Saito et al., 2009;
van Marken Lichtenbelt et al., 2009). Indeed, individuals with
low levels of BAT activity are more susceptible to developing
CMDs (Mattson, 2010) and, as we previously proposed, the rate
of aging is determined, at least in part, through changes in
BAT activity (Carrillo and Flouris, 2011; Flouris and Piantoni,
2015). In addition to age- and adiposity-associated loss of BAT
activity, UCP1 gene variants may also increase one’s tendency
for developing CMDs by disrupting regular BAT function (Jia
et al., 2010). In this light, BAT activation is impaired in healthy
individuals carrying specific UCP1 gene variants (Nagai et al.,
2007), corroborating a role of UCP1 gene variation in adverse
metabolic processes and susceptibility to CMDs. Experimental
animal evidence supports a relationship between BAT activity
and energy homeostasis. For instance, inactivation of UCP1 due
to thermoneutral conditions led to obesity in mice fed both
a control diet and high-fat diet, indicating a role of BAT in
maintaining a non-obese phenotype (Feldmann et al., 2009). On
the other hand, overexpression of UCP1 in white adipose tissue
and skeletal muscle of mice, provided protection against diet-
induced obesity, increased energy expenditure, and improved
glucose homeostasis (Keipert et al., 2013; Ost et al., 2014). In
addition, embryonic BAT transplants have been shown to reverse
type 1 diabetes in mice in an insulin receptor activity-dependent
mechanism suggesting an important role of BAT in whole-body
metabolism (Gunawardana and Piston, 2012).
The current NCBI database of genetic variations shows more
than 2300 single nucleotide polymorphisms (SNPs) associated
with the UCP1 gene (Sherry et al., 2001). The intron–exon
structure of the UCP1 gene is illustrated in Figure 2. Several
studies have investigated the prevalence of such UCP1 gene
variants and their influence on the susceptibility to CMDs,
though data still remain scarce among different ethnic groups in
Europe. Indeed frequencies for most UCP1 gene variants have
been estimated in selective ethnic groups with small number of
participants, rarely reaching more than a few hundreds. Further,
the available studies have focused on certain polymorphisms -
3826A/G, -112A/C, and -1766A/G in the 5′-region, Ala64Thr in
exon 2, and Met229Leu in exon 5 of the gene (reviewed in Jia
et al., 2010; Brondani et al., 2012). In addition, emerging evidence
of CVD prevalence rates being the highest globally among ethnic
groups in Eastern Europe and Western Asia (Balkau et al., 2007),
suggests investigation of the effect of UCP1 gene variants on
CMD predisposition across these regions. Therefore, accurate
estimation of the prevalence of the most commonly studied UCP1
gene variants and identification of ethnic groups at high risk
of developing CMDs warrants further analysis in large cohorts
of patients and healthy controls. Integration of the findings to
national public health policies may substantially improve CMD
preventive and management strategies.
THE HYPOTHESIS OF THE UCP1
GENETIC VARIATION EFFECT ON THE
INTERETHNIC DIFFERENCES IN CMD
PREVALENCE RATES
On the grounds of experimental evidence corroborating an
association of UCP1 gene variants and CMDs, we hypothesize
that the ethnic-specific predisposition to CMDs could be
attributed, at least partially, to the diverse prevalence of specific
UCP1 gene variants among different ethnic groups. Such an
increased susceptibility to the development of CMDs has been
observed specifically in ethnic groups in Eastern Europe and
Western Asia (Figure 1). Large population-based studies are thus
required to investigate the CMD-related association of specific
UCP1 gene variants among different ethnic groups. Information
on ethnic-specific genotypes’ frequencies of the analyzed UCP1
gene variants could be used to identify those ethnic groups at
high-risk of developing CMDs, and further explain to an extent
the high CMD prevalence rates observed in Eastern Europe and
Western Asia.
Evaluation of the Ethnic-Specific UCP1
Gene Variants in CMD Susceptibility and
Prevalence Rates
Due to its aforementioned role in the regulation of energy
metabolism, UCP1 has been considered a potential genetic risk
factor for predisposition to CMDs (Feldmann et al., 2009; Jia
et al., 2010). For that reason, numerous genetic association
studies in selective European populations have been performed to
explore a potential link between UCP1 gene variants and CMDs,
often yielding to controversial results. A number of independent
genetic association studies suggested an association between
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FIGURE 1 | Map of Europe and Western Asia showing the distribution of cardiovascular mortality rates in males (A) and females (B), adapted from the
World Health Organization (WHO, 2011) (age standardized, per 100 000).
UCP1 gene variants and obesity, type 2 diabetes mellitus, body
fat distribution, and metabolic syndrome-related traits (Clement
et al., 1996; Hamann et al., 1998; Kiec-Wilk et al., 2002; Forga
et al., 2003; Herrmann et al., 2003; Ramis et al., 2004; Sramkova
et al., 2007), while other studies failed to demonstrate such
correlations (Urhammer et al., 1997; Fogelholm et al., 1998;
Gagnon et al., 1998; Sivenius et al., 2000; Nieters et al., 2002;
Malczewska-Malec et al., 2004; Mottagui-Tabar et al., 2008). The
most commonly studied UCP1 gene variant is -3826A/G, while
the synergistic effect of several variants in UCP1 gene has been
investigated to a lesser extent (reviewed in Brondani et al., 2012).
To our knowledge, there has been no genetic association study to
investigate the combined effect of the most common UCP1 gene
variants on the susceptibility to CMDs among different ethnic
groups in Europe.
On the other hand, differences in the number of UPC1
polymorphism carriers have been reported in various populations
(Jia et al., 2010). However, given the relatively low prevalence
of UCP1 gene polymorphisms [can be as low as 2 or 6% for
specific polymorphisms (Vimaleswaran et al., 2007)], these data
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FIGURE 2 | Intron–exon structure of the UCP1 gene is shown (green blocks) according to two predicted transcripts (XM_005263206.2 and
XM_011532228.1 with corresponding protein forms XP_005263263.1 and XP_011530530.1). Protein coding regions are shown by orange blocks, coding
sequence of UCP1 gene is in reverse chromosome DNA strand. Position of XM_005263206.2 in genome is indicated (140,559,394 . . . 140,568,902 bp). Seven
mostly investigated variants of the UCP1 gene are located on the map: -3826A/G (rs1800592), -3737C/A (rs7687015), -1766A/G (rs3811791), -412A/C
(rs3811787), -112A/C (rs10011540), Arg64Thr (rs45539933), Met229Leu (rs2270565). Distribution of known genetic variants along the locus is shown at the bottom
(blue bars).
are limited by the small sample sizes assessed (<500 participants)
(Kogure et al., 1998; Hayakawa et al., 1999; Nakano et al.,
2006). Small study populations limit the accuracy of genotype
prevalence estimates (e.g., only 10 identified individuals in a
study of 200 participants with a 5% UCP1 gene polymorphism
prevalence rate), making it difficult to integrate the evidence
and, thus, to easily translate the findings into public health
improvements (Ioannidis et al., 2001; Chang et al., 2009).
More recent studies investigating the prevalence of genetic
polymorphisms and their impact on health and disease included
thousands of participants among diverse populations (Yoshida
et al., 2009). Given also the increased CMD prevalence rates
specifically in ethnic groups in Eastern Europe and Western Asia,
it is expected that large case-control, population-based studies
will identify those UCP1 gene variants that predispose ethnic
groups across these regions to CMD development. Despite their
increased cost, such studies will potentially explain the highest
CMD prevalence rates observed across these regions at a global
level.
Further studies to investigate a synergistic effect of the
studied UCP1 gene variants with environmental (geographical
location, climate, diet, and physical activity) and/or socio-
economic (education, income, and cultural conception) factors
could significantly contribute to define the association between
the genetic variation in UCP1 gene and CMDs, by fully
adjusting for such potential confounders. The emerging field
of human social genomics highlights the importance of the
contemporary dynamic social adverse conditions on influencing
ones genotype and hence further shaping the susceptibility to
chronic diseases. On the other hand, gene variants can also
alter genotypic response to socio-environmental adversities by
activating different molecular pathways and factors, and thus
enhancing or reducing the risk for chronic disease (Slavich and
Cole, 2013). Future investigation to address such dynamic effects
of external social environment on UCP1 gene expression may
also reveal additional factors, such as experience of chronic social
isolation and isolation of obese individuals, which could in turn
either enhance or reduce the impact of specific UCP1 gene
variants on ethnic-specific predisposition to CMDs.
We propose to investigate the putative association of the
several UCP1 gene variants with the development of CMDs.
All patients and volunteers in this study will derive from
six different ethnic groups, with ethnicity to be defined by
self-report. Our sample population will be comprised of 1500
unrelated individuals aged of >18 years diagnosed with type-
2 diabetes, obesity, and metabolic syndrome with or without
hypertension. Our control group will contain 1500 age- and
gender-matched healthy individuals. Exclusion criteria will
include individuals < 18 years of age, smoking, history of eating
disorder, pregnancy or lactation, acute illness and/or infection
(last 4 weeks). Participants will be white Caucasians of European
and Western Asian origin. They will be weighed, their height will
be measured, and their BMI will be calculated. Blood pressure will
be assessed. Percent body fat will be measured three times, and
waist-to-hip ratio will be calculated. Further, after an overnight
fast, plasma glucose will be measured. Environmental and socio-
economic factors will be determined by using standardized
questionnaires. The seven most commonly studied UCP1 gene
variants (Figure 2) will be genotyped. Genomic DNA will be
extracted from whole blood and each UCP1 gene variant will
be assessed by Real Time Taqman method. To our knowledge
only three studies have conducted in vitro or in vivo studies
to characterize the function of two specific UCP1 gene variants
(rs1800592 and rs7687015) (Esterbauer et al., 1998; Rose et al.,
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2011; Brondani et al., 2012). We aim, therefore, to assess the
putative functional relevance of specific alleles and haplotypes
of the aforementioned variants on the transcriptional activity of
UCP1 by in vitro reporter assays. Appropriate statistical analysis
will be used to investigate the associations of UCP1 variant-
specific alleles and haplotypes with CMDs, and in relation with
clinical characteristics. The modifying effect of environmental
factors, with a special focus on diet variation among the different
ethnic groups studied, on the association between CMDs and
UCP1 gene variants will also be examined. Further, the effect
of socio-economic factors on UCP1 transcriptional activity as
putatively mediated by the analyzed alleles and haplotypes of
UCP1 gene variants will also be determined.
This proposed investigation of the combined effect of the most
commonly studied UCP1 gene variants on CMD prevalence in a
very large and ethnically diverse sample of patients and healthy
individuals will identify high-risk ethnic groups for developing
CMDs. Further, the study of UCP1 gene variants-environment
interactions will define a strong association between UCP1 gene
variants and CMD development.
ASSESSMENT OF THE CLINICAL
IMPLICATIONS AND THE IMPACT OF
UCP1 GENE VARIANTS ON PUBLIC
HEALTH CARE SYSTEM, POLICY AND
PREVENTIVE PRACTICES
Cardio-metabolic diseases constitute a serious public health
concern with a substantial impact not only on life expectancy
(Calle and Kaaks, 2004; Poirier et al., 2006; WHO, 2011, 2014;
Cornelissen and Smart, 2013; Conn et al., 2014) but also on
healthcare services at a major cost to the economy (WHO,
2007). A substantial economic pressure on healthcare systems is
imposed by CVDs across Europe, reaching €196 billion per year
(Nichols et al., 2012). Recent reports predict a 33% increase in the
global market for drugs treating CVDs from 2012 to 2019 (Gbi
research, 2013). Further, USA comprise the biggest single market
for anti-obesity drugs, with around 68% of the population either
overweight or obese, followed by the UK and other European
countries (Holvoet, 2012).
Despite the growing cost of anti-CMD agents, there is
concern that the drugs fail to provide lasting benefits for
health and well-being (Huntington and Shewmake, 2010). In
this light, identification of interethnic differences in UCP1
gene variants that could predispose certain ethnic groups
to the development of CMDs could assist in the design of
effective preventive and management practices, with beneficial
outcomes for the public health care services. UCP1 gene
variants have been associated with high levels of low-density
lipoprotein (LDL) cholesterol and diastolic blood pressure,
as well as with low levels of high-density lipoprotein (HDL)
cholesterol (Kiec-Wilk et al., 2002; Oh et al., 2004). In turn,
high levels of circulating LDL cholesterol are implicated in
the development of atherosclerosis and represent important
pharmacological target in preventing the progression of
atherosclerosis and event of coronary heart disease and stroke
(Takahashi et al., 2010). Therefore, it is evident that a fresh
perspective in targeted interventions is necessary to efficiently
manage the massive projected increase of CMDs over the next
decades.
The diverse distribution of CMDs among different ethnic
groups could be also attributed to environmental factors, and
socio-economic factors. WHO estimates that more than 80%
of CVDs and diabetes deaths occur in low-and middle-income
countries (WHO, 2016a,b). It is therefore crucial to determine the
potential modifying effects of the environmental factors on the
UCP1 gene variation risk pattern of CMD development. Lastly, in
light of a growing body of evidence, the once accepted conception
on an otherwise stable and impermeable genetic make-up
has been challenged, supporting reciprocal gene-adverse social
environment interactions, with putative strong impact on the
role of certain UCP1 gene variants in defining ethnic-specific
susceptibility to CMDs.
CONCLUSION
The association between specific UCP1 gene variants and CMDs
has been investigated in certain ethnic groups, often leading
to controversial results. There is the need to improve our
understanding on the prevalence of the most commonly studied
UCP1 gene variants among various ethnic groups and their
impact on the predisposition to CMDs. It can be hypothesized
that interethnic differences in the distribution of UCP1 gene
variants could account, at least in part, for such a diverse
population-specific predisposition to CMDs. One such example
of a wide variation in CMD prevalence rates has been observed
across Europe and Western Asia. Addressing this hypothesis
in multi-ethnic based studies will provide information on the
functional effect of these genetic variants on the pathogenetic
mechanisms of CMDs. Identifying high-risk ethnic groups of
developing CMDs will set the ground for defining public health
policies and improving existing preventive and management
strategies.
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